Physician profile
John Thomas Kuhl
NPI 1205814613
$5,776.07
in general payments reported to CMS, 2019-2025
33 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $53.76 · 2021: $161 · 2022: $1,015 · 2023: $1,304 · 2024: $1,746 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,208 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,208.08 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $552.18 | 2019-2025 | Ilumya, Winlevi |
| Janssen Biotech, INC. | $507.86 | 2019-2025 | Tremfya |
| Abbvie INC. | $418.84 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $379.10 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $367.96 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $353.51 | 2019-2025 | |
| Amgen INC. | $340.88 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $337.67 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $296.26 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $290.24 | 2021-2025 | Jublia, Siliq, Cabtreo |
| Novartis Pharmaceuticals Corporation | $280.98 | 2019-2025 | |
| Ucb, INC. | $245.74 | 2019-2025 | Bimzelx |
| Incyte Corporation | $217.47 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $196.35 | 2019-2025 | Adbry, Spevigo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.09 | 2022-2025 | Spevigo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $108.22 | 2025 | Affinity, Simplimax |
| Dermavant Sciences, INC. | $97.32 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $95.41 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $83.19 | 2024-2025 | |
| Biofrontera INC. | $68.05 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $63.23 | 2024-2025 | Hadlima |
| Genentech USA, INC. | $36.80 | 2019 | |
| Celgene Corporation | $36.70 | 2019 | |
| Paratek Pharmaceuticals, INC. | $35.37 | 2022 | |
| Mallinckrodt Hospital Products INC. | $31.09 | 2025 | Acthar |
| Journey Medical Corporation | $24.98 | 2022 | |
| Merck Sharp & Dohme LLC | $24.01 | 2024 | Keytruda |
| Botanix Sb INC | $22.72 | 2025 | Sofdra |
| Prugen, INC. Pharmaceuticals | $22.21 | 2019 | |
| Lnhc, INC | $19.31 | 2025 | Zelsuvmi |
| Krystal Biotech INC | $18.24 | 2024 | Vyjuvek |
| Verrica Pharmaceuticals INC. | $17.14 | 2025 | Ycanth |
| Epi Health, LLC | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kuhl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.